Apr 24, 2025

Cordis Announces Positive Results from Two Major Clinical Studies.

Cordis Announces Positive Results from Two Major Studies Demonstrating Durable Efficacy of SELUTION SLR Drug-Eluting Balloon in Complex Peripheral Artery Disease Patients.

Read more

Jun 18, 2024

Cordis Announces Positive 24-Month Results from the SELUTION Superficial Femoral Artery (SFA) Japan Study

Read more

Nov 16, 2023

Cordis Announces Enrollment Completion of the RADIANCY Clinical Study in Europe

Read more

Nov 6, 2023

Cordis Announces Scott Drake as Chief Executive Officer

Cordis Announces Scott Drake as Chief Executive Officer

Read more

Oct 31, 2023

World's First Patient Enrolled in SELUTION4DeNovo DEB IDE Trial

Read more

Oct 24, 2023

Patient enrollment in SELUTION SLR™ DEB SUCCESS PTA Study

Cordis announces the completion of patient enrollment in SELUTION SLR^™ DEB SUCCESS PTA Study

Read more

Oct 2, 2023

Cordis Announces the Completed Acquisition of MedAlliance

Read more

Sep 5, 2023

Cordis Names Scott Drake Executive Chairman

Read more

Oct 17, 2022

Cordis Announces Acquisition of MedAlliance

Cordis Announces Acquisition of MedAlliance, Positioning Itself for Market Leadership in Drug-Eluting Balloon Technology

Read more